Celltrion to acquire Eli Lilly plant in U.S. as part of tariff strategy

Celltrion signed a $330 million deal on Tuesday to acquire an Eli Lilly and Company biopharmaceutical plant in New Jersey, securing a U.S. production base as part of its strategy to reduce tariff risks.

2025-09-23

Wegovy maker Novo Nordisk to slash 9,000 jobs as competition heats up

Novo Nordisk will cut 9,000 jobs and restructure to save $1.3 billion annually amid increased competition for Wegovy and Ozempic, expecting slower growth.

2025-09-10

Eli Lilly's Mounjaro to land in Korea, setting off price war with Wegovy

Eli Lilly’s cut-price Mounjaro lands in Korea next week, ending Novo Nordisk’s domestic monopoly and igniting a price war in the weight loss drug market, while Wegovy will switch to tiered pricing in a global first.

2025-08-13

Olix, Eli Lilly to develop liver disease drug under $630 million deal

Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and metabolic diseases.

2025-02-10

Hanmi seeks to gain on Wegovy with its own weight-loss drug

Hanmi Pharmaceutical is working on its own range of weight-loss treatments tailored to the Korean market.

2025-01-16

Korean pharmas jump on weight loss drug boom

The popularity of Novo Nordisk's weight-loss drug Wegovy has made the Danish company the most valuable in Europe; Korean pharmas are now seeking a share of the lifestyle drugs market.

2023-09-20

Samsung Biologics produces Lilly Covid-19 treatment

Samsung Biologics is mass producing Eli Lilly’s antibody treatment for the new coronavirus, the Korean biopharmaceutical company said Tuesday.

2020-11-17

korea joongAng daily